MetaCap

LENZ Therapeutics (LENZ) vs Zura Bio (ZURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zura Bio (ZURA) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 74.4% versus a loss of 90.0%. LENZ Therapeutics is the larger company by market cap ($93.2 million vs $89.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LENZ-89.97%ZURA-74.37%
+103%+2%-99%
Nov 21, 20251 yearNov 20, 2026
LENZ-82.71%ZURA-96.84%
+198%+44%-111%
Mar 20, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LENZ versus ZURA key metrics
MetricLENZZURA
Share price$2.97$0.9305
Market cap$93.16M$89.63M
1-day change-11.23%-2.30%
YTD return-81.47%-82.24%
1-year return-89.97%-74.37%
5-year return-95.57%—
EPS (TTM)$-4.53$-1.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$19.09M—
Net income (latest FY)$-82.13M$-68.65M
Gross margin97.81%—
Operating margin-477.46%—
Net margin-430.25%—
52-week high$32.13$7.44
52-week low$2.80$0.919
Distance from 52-week high-90.77%-87.49%
Analyst consensusnonestrong_buy
Avg. price target upside+400.17%+759.75%
Average volume892.30K4.47M
Shares outstanding31.42M96.33M
Employees4040
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZURA has outperformed LENZ by 15.6 percentage points over the past year.

About LENZ Therapeutics

LENZ stock →

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

About Zura Bio

ZURA stock →

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

LENZ vs ZURA FAQ

Which is bigger, LENZ Therapeutics or Zura Bio?

LENZ Therapeutics (LENZ) is larger, with a market capitalization of $93.16M compared with $89.63M for Zura Bio (ZURA).

Which stock has performed better over the past year, LENZ or ZURA?

ZURA returned -74.37% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.

Are LENZ Therapeutics and Zura Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons